Roth Capital affirms Curis, Inc. (Nasdaq: CRIS) with a Buy rating and $5 price target following Q4/FY15 results released earlier.

Analyst Joseph Pantginis commented today, The focus for Curis this year will be driving the Phase II CUDC-907 program forward in DLBCL patients as well as having the first two candidates from the Aurigene collaboration enter the clinic. The '907 program is an ongoing randomized Phase II study in multiple relapse DLBCL patients with Myc mutations. The study will enroll ~120 patients receiving '907 +/- Rituxan. The primary endpoint will be objective response rate with secondary endpoints of PFS, OS and durability or responses. The company expects enrollment to take 12-15 months. If the monotherapy arm shows encouraging response rates, the arm would be expanded followed by the company seeking accelerated approval from the FDA. Full approval could come from the combination arm with Rituxan. The program is also expected to move into solid tumors and ISTs in medulloblatoma and neuroblastoma.

For an analyst ratings summary and ratings history on Curis click here. For more ratings news on Curis click here.